| Name | SCD1 inhibitor-3 |
|---|---|
| Synonyms |
1H-Pyrazole-3-cboxamide, 5-[1-[(4-fluorophenyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-(3-pyridinylmethyl)
FUN06487 5-{1-[(4-fluorophenyl)methyl]-5-oxo-4,5-dihydro-1H-1,2,4-triazol-4-yl}-N-[(pyridin-3-yl)methyl]-1H-pyrazole-3-cboxamide SCD1 inhibitor-3, 10 mM in DMSO |
| Description | SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
SCD1[1] |
| In Vivo | SCD1 inhibitor-3 (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %[1]. SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1]. Animal Model: Lewis rats Dosage: 5 mg/kg Administration: P.o.; 4 hours Result: Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %. Animal Model: Lewis rats Dosage: 2~10 mg/kg Administration: P.o.; 4 hours Result: A dose-responsive reduction of plasma triglycerides desaturation index. |
| References |
| Molecular Formula | C19H16FN7O2 |
|---|---|
| Molecular Weight | 393.37 |